The document discusses best practices for communicating disease state information internally at pharmaceutical companies, highlighting the importance of a structured approach including clear objectives, tight message control, and testing messages. It provides insights from interviews with industry executives on topics such as effective communication channels, success factors, and challenges of products treating sensitive conditions. The report is intended to help brand leaders understand how to deliver the right disease state information to employees.